The NIAID CIVICs Program was recently featured in a special issue of the journal Vaccine. A variety of CIVICs-funded vaccine studies and promising candidates were highlighted in this issue.
Escalera Merino deepened her understanding on the role of mutations in the SARS-CoV-2 spike protein during her training on effector function assays in Dr. Taia Wang’s lab.
Wiggins visited Dr. Andrea Sant’s lab to deepen her understanding of CD4+ T-cell responses to a COBRA-designed influenza vaccine candidate administered to obese mouse models.
NIAID hosted the 2024 CIVICs Annual Network Meeting (ANM) from August 4-7 in Bethesda, Maryland for nearly 370 virtual and in-person attendees. The meeting featured engaging discussion and presentations from recent scientific achievements across CIVICs. The meeting concluded with the first-ever CIVICs industry day.
Ted Ross, Principal Investigator of CIVR-HRP, has been featured on multiple media platforms to discuss his innovative research and how it moves the needle for influenza vaccine science.
André León discusses his experience studying influenza coast to coast. Follow his journey to New York City for virology training in the Krammer lab!
For decades, data sharing practices played a key role in advancing the structural biology field, providing opportunities for technical skill development and promoting data rigor and reproducibility. Data sharing success can be largely attributed to widespread recognition of its importance amongst the research community, and its role in shepherding the future of structural biology discoveries.
Dr. Kathleen Neuzil leaves the University of Maryland to serve as the Director of NIH’s Fogarty International Center and Dr. Justin Ortiz assumes the role of PI of the UMB CIVICs Clinical Core.
World-renowned influenza immunity and vaccine development expert, Florian Krammer, Ph.D., has assumed a new role as Professor of Infection Medicine at the University of Vienna.
Researchers at CIVR-HRP demonstrated that previously generated data from mouse and ferret studies can be repurposed to produce novel findings. In 2020, they found antigenic distance measures (ADM) correlated to antibody responses and clinical outcomes to influenza vaccination and infection.